A chimeric protein that functions as both an anthrax dual-target antitoxin and a trivalent vaccine.
Effective measures for the prophylaxis and treatment of anthrax are still required for counteracting the threat posed by inhalation anthrax. In this study, we first demonstrated that the chimeric protein LFn-PA, created by fusing the protective antigen (PA)-binding domain of lethal factor (LFn) to PA, retained the functions of the respective molecules. On the basis of this observation, we attempted to develop an antitoxin that targets the binding of lethal factor (LF) and/or edema factor (EF) to PA and the transportation of LF/EF. Therefore, we replaced PA in LFn-PA with a dominant-negative inhibitory PA (DPA), i.e., PA(F427D). In in vitro models of anthrax intoxication, the LFn-DPA chimera showed 3-fold and 2-fold higher potencies than DPA in protecting sensitive cells against anthrax lethal toxin (LeTx) and edema toxin (EdTx), respectively. In animal models, LFn-DPA exhibited strong potency in rescuing mice from lethal challenge with LeTx. We also evaluated the immunogenicity and immunoprotective efficacy of LFn-DPA as an anthrax vaccine candidate. In comparison with recombinant PA, LFn-DPA induced significantly higher levels of the anti-PA immune response. Moreover, LFn-DPA elicited an anti-LF antibody response that could cross-react with EF. Mice immunized with LFn-DPA tolerated a LeTx challenge that was 5 times its 50% lethal dose. Thus, LFn-DPA represents a highly effective trivalent vaccine candidate for both preexposure and postexposure vaccination. Overall, we have developed a novel and dually functional reagent for the prophylaxis and treatment of anthrax.
Wu
Gaobing
G
State Key Laboratory of Agricultural Microbiology, College of Life Science and Technology, Huazhong Agricultural University, Shizishan Street 1, Wuhan, People's Republic of China.
Hong
Yuzhi
Y
Guo
Aizhen
A
Feng
Chunfang
C
Cao
Sha
S
Zhang
Cheng-Cai
CC
Shi
Ruiping
R
Tan
Yadi
Y
Liu
Ziduo
Z
D000818:Animals; D000881:Anthrax / Q000276:immunology* / Q000517:prevention & control; D022122:Anthrax Vaccines / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D000942:Antigens, Bacterial / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D000992:Antitoxins / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D001427:Bacterial Toxins / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D002460:Cell Line; D004591:Electrophoresis, Polyacrylamide Gel; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D051379:Mice; D008807:Mice, Inbred BALB C; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000276:immunology* / Q000378:metabolism
D022122:Anthrax Vaccines; D000942:Antigens, Bacterial; D000992:Antitoxins; D001427:Bacterial Toxins; D011993:Recombinant Fusion Proteins; C030325:anthrax toxin